The inhibition of Src family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion

Pancreas

Volumn 43, Issue 5, 2014, Pages 768-776

  Je, Dong Wook ^a   Moon O, Young ^a   Ji, Young Geon ^b   Cho, Yunkyung ^b   Lee, Dong Hyeon ^a  

^a CHA University   (South Korea)

^b CHA University   (South Korea)

Author keywords

Invasion; Migration; Pancreatic cancer; Proliferation; SiRNA; Src family kinase

Indexed keywords

HEMATOPOIETIC CELL KINASE; MESSENGER RNA; PROTEIN KINASE FER; PROTEIN KINASE FYN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; A 419259; FRK PROTEIN, HUMAN; FYN PROTEIN, HUMAN; HCK PROTEIN, HUMAN; LYN PROTEIN-TYROSINE KINASE; PROTEIN KINASE P60; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR PROTEIN; YES1 PROTEIN, HUMAN;

ARTICLE; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL MOTION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-FYN; PROTO-ONCOGENE PROTEINS C-HCK; PROTO-ONCOGENE PROTEINS C-YES; PROTO-ONCOGENE PROTEINS PP60(C-SRC); PYRIMIDINES; PYRROLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SRC-FAMILY KINASES;

EID: 84902455490     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000103     Document Type: Article

References (42)

1. Li J, Wientjes MG, Au JL. Pancreatic cancer: Pathobiology, treatment options, and drug delivery. AAPS J. 2010;12:223-232.
2. Borja-Cacho D, Jensen EH, Saluja AK, et al. Molecular targeted therapies for pancreatic cancer. Am J Surg. 2008;196:430-441.
3. Van Laethem JL, Verslype C, Iovanna JL, et al. New strategies and designs in pancreatic cancer research: Consensus guidelines report from a European expert panel. Ann Oncol. 2012;23:570-576.
4. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60:2926-2935. (Pubitemid 30395817)
5. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. Oncologist. 2009;14:667-678.
6. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19:5636-5642.
7. Puls LN, Eadens M, Messersmith W. Current status of SRC inhibitors in solid tumor malignancies. Oncologist. 2011;16:566-578.
8. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control. 2000;7:421-427.
9. Lutz MP, Esser IB, Flossmann-Kast BB, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun. 1998;243:503-508. (Pubitemid 28414054)
10. Rajeshkumar NV, Tan AC, De Oliveira E, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res. 2009;15:4138-4146.
11. Messersmith WA, Rajeshkumar NV, Tan AC, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther. 2009;8:1484-1493.
12. Ito H, Gardner-Thorpe J, Zinner MJ, et al. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery. 2003;134:221-226. (Pubitemid 37070342)
13. Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res. 2004;10:8028-8036. (Pubitemid 39587544)
14. Lieber M, Mazzetta J, Nelson-Rees W, et al. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer. 1975;15:741-747.
15. Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: Sensitivity to asparaginase. Int J Cancer. 1977;19:128-135. (Pubitemid 8016933)
16. Lee DH, Chung K, Song JA, et al. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. J Proteome Res. 2010;9:5668-5676.
17. Lee DH, Ko JJ, Ji YG, et al. Proteomic identification of RREB1, PDE6B, and CD209 up-regulated in primitive gut tube differentiated from human embryonic stem cells. Pancreas. 2012;41:65-73.
18. Choi JH, Ji YG, Lee DH. Uridine triphosphate increases proliferation of human cancerous pancreatic duct epithelial cells by activating P2-2 receptor. Pancreas. 2013;42:680-686.
19. Choi JH, Lee MY, Ramakrishna S, et al. LCP1 up-regulated by partial pancreatectomy supports cell proliferation and differentiation. Mol Biosyst. 2011;7:3104-3111.
20. Brandvold KR, Steffey ME, Fox CC, et al. Development of a highly selective c-Src kinase inhibitor. ACS Chem Biol. 2012;7:1393-1398.
21. Wilson MB, Schreiner SJ, Choi HJ, et al. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene. 2002;21:8075-8088. (Pubitemid 35454411)
22. Plé PA, Green TP, Hennequin LF, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem. 2004;47:871-887. (Pubitemid 38176790)
23. Nagaraj NS, Smith JJ, Revetta F, et al. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther. 2010;9:2322-2332.
24. Fu Y, Zagozdzon R, Avraham R, et al. CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion. Int J Oncol. 2006;29:1453-1458.
25. Chen ZY, Cai L, Zhu J, et al. Fyn requires HnRNPA2B1 and Sam68 to synergistically regulate apoptosis in pancreatic cancer. Carcinogenesis. 2011;32:1419-1426.
26. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401. (Pubitemid 38938156)
27. Duxbury MS, Ito H, Zinner MJ, et al. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004;10:2307-2318. (Pubitemid 38445688)
28. Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A. 2001;98:7319-7324. (Pubitemid 32567946)
29. Boyer B, Bourgeois Y, Poupon MF. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene. 2002;21:2347-2356. (Pubitemid 34407294)
30. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337-358. (Pubitemid 36791891)
31. Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010; 223:14-26.
32. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006;168:962-972. (Pubitemid 43327748)
33. Lowell CA, Soriano P. Knockouts of Src-family kinases: Stiff bones, wimpy T cells, and bad memories. Genes Dev. 1996;10:1845-1857. (Pubitemid 26281680)
34. Chandrasekharan S, Qiu TH, Alkharouf N, et al. Characterization of mice deficient in the Src family nonreceptor tyrosine kinase Frk/rak. Mol Cell Biol. 2002;22:5235-5247. (Pubitemid 34700712)
35. Zhou X, Hua L, Zhang W, et al. FRK controls migration and invasion of human glioma cells by regulating JNK/c-Jun signaling. J Neurooncol. 2012;110:9-19.
36. Bhattacharjee A, Pal S, Feldman GM, et al. Hck is a key regulator of gene expression in alternatively activated human monocytes. J Biol Chem. 2011;286:36709-36723.
37. Pene-Dumitrescu T, Peterson LF, Donato NJ, et al. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene. 2008;27:7055-7069.
38. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6:587-595.
39. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494-498. (Pubitemid 32494397)
40. Bjorge JD, Pang AS, Funnell M, et al. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS One. 2011;6:e19309.
41. Palliser D, Chowdhury D,Wang QY, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006;439:89-94. (Pubitemid 43053634)
42. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067-1070.